InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,221.19
(
0.00%
)
US TECH 100
17,736.80
(
0.08%
)
Dow Jones
39,428.62
(
-0.01%
)
Brent Oil
82.12
(
-1.32%
)
Bitcoin
61,490.20
(
-2.25%
)
Post# of 470
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Drugdoctor

Send PM Follow Ignore
Followers 1741
Posts 142068
Boards Moderated 4
Alias Born 09/11/2005

Drugdoctor

Re: island man post# 147

Friday, 03/17/2017 8:54:00 AM

Friday, March 17, 2017 8:54:00 AM

Post# of 470
I agree, ZACK's has $6 price target... http://finance.yahoo.com/news/arlz-2016-financial-results-guidance-170000102.html

Our valuation is based on an enterprise value (EV)/revenues multiple of 5.0x on projected 2021 revenues of $199 million using a 15% discount rate. The company currently has $274 million in debt and approximately $65 million in cash at the end of 2016. This leads to a valuation of approximately $6 per share. This is significantly lower than our previous target price, however it is the result of having to significantly lower our projections of YOSPRALA® revenue based on how the drug is selling now.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up